Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.
J Dig Dis. 2023 Apr;24(4):244-261. doi: 10.1111/1751-2980.13195. Epub 2023 Jul 4.
Given the scale and persistence of coronavirus disease 2019 (COVID-19), significant attention has been devoted to understanding the relationship between human gut microbiota and COVID-19. In this systematic review we aimed to comprehensively assess the gut microbiota composition in patients infected with COVID-19 and those recovered from COVID-19 in comparison to healthy controls (HCs).
Peer-reviewed articles and preprints published up to September 1, 2022, were searched in Ovid MEDLINE, Ovid EMBASE, and SCOPUS. Observational studies reporting the gut microbiota profile in adult (≥18 years) COVID-19 patients or those recovered from COVID-19 compared to HCs were eligible for inclusion in this systematic review. The quality assessment of studies was performed using the Newcastle-Ottawa scale.
We identified 27 studies comprising 18 studies that compared COVID-19 patients and six that compared recovered COVID-19 patients to HCs, while the other three studies compared both COVID-19 and recovered COVID-19 patients to HCs. Compared to HCs, decreased gut microbial diversity and richness and a distinctive microbial composition were reported in COVID-19 patients and recovered COVID-19 patients. In COVID-19 patients, Bacteroidetes were found to be enriched, and Firmicutes depleted. Decreased short-chain fatty acid (SCFA)-producing bacteria, such as Faecalibacterium, Ruminococcus, and Bifidobacterium, among others, were also observed in COVID-19 patients, which were not restored to normal levels in those who recovered.
Gut dysbiosis was evident in COVID-19, and available data suggested that dysbiosis persisted even in recovered COVID-19 patients, with decreased Firmicutes and SCFA-producing bacteria.
鉴于 2019 年冠状病毒病(COVID-19)的规模和持续时间,人们高度关注人类肠道微生物群与 COVID-19 之间的关系。在本系统评价中,我们旨在全面评估感染 COVID-19 的患者和从 COVID-19 中康复的患者与健康对照(HCs)的肠道微生物群组成。
在 Ovid MEDLINE、Ovid EMBASE 和 SCOPUS 中检索截至 2022 年 9 月 1 日发表的同行评审文章和预印本。符合纳入标准的研究为报告成年(≥18 岁)COVID-19 患者或从 COVID-19 中康复的患者肠道微生物群特征,并与 HCs 进行比较的观察性研究。使用纽卡斯尔-渥太华量表对研究进行质量评估。
我们确定了 27 项研究,其中 18 项研究比较了 COVID-19 患者和 6 项研究比较了康复的 COVID-19 患者与 HCs,而另外 3 项研究比较了 COVID-19 患者和康复的 COVID-19 患者与 HCs。与 HCs 相比,COVID-19 患者和康复的 COVID-19 患者的肠道微生物多样性和丰富度降低,微生物组成独特。在 COVID-19 患者中,发现厚壁菌门增多,拟杆菌门减少。还观察到 COVID-19 患者中短链脂肪酸(SCFA)产生菌,如粪杆菌、真杆菌和双歧杆菌等减少,而在康复患者中并未恢复到正常水平。
COVID-19 中存在肠道菌群失调,现有数据表明,即使在康复的 COVID-19 患者中,菌群失调仍然存在,厚壁菌门和产生 SCFA 的细菌减少。